Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C3AR1 | Q16581 | 1/20 | 0.39 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.35 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.34 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KLK7 | P49862 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.32 |
| ▸ | OTC | P00480 | 1/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.31 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.31 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.31 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27844592 | 1.00 | C3AR1 (0.39) | C3AR1SIRT5CACNA1BCTDSP1SHMT1 | |
| SCHEMBL93363 | 0.86 | C3AR1 (0.47) | C3AR1CACNA1BCTDSP1SHMT1MEN1 | |
| SCHEMBL93364 | 0.86 | C3AR1 (0.47) | C3AR1CACNA1BCTDSP1SHMT1MEN1 | |
| SCHEMBL30404095 | 0.86 | C3AR1 (0.47) | C3AR1CACNA1BCTDSP1SHMT1MEN1 | |
| SCHEMBL2762953 | 0.83 | C3AR1 (0.38) | C3AR1SIRT5CTDSP1SHMT1MEN1 | |
| SCHEMBL24531193 | 0.82 | C3AR1 (0.38) | C3AR1SIRT5CACNA1BCTDSP1SHMT1 | |
| SCHEMBL15315075 | 0.82 | C3AR1 (0.38) | C3AR1SIRT5CACNA1BCTDSP1SHMT1 | |
| SCHEMBL10441955 | 0.82 | C3AR1 (0.38) | C3AR1SIRT5CACNA1BCTDSP1SHMT1 | |
| SCHEMBL15691795 | 0.82 | C3AR1 (0.38) | C3AR1SIRT5CACNA1BCTDSP1SHMT1 | |
| SCHEMBL25356845 | 0.81 | FOLH1 (0.45) | C3AR1SIRT5CTDSP1SMN1; SMN2FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013004716-A1 | PEPTIDE BEADS | UNIVERSITÄT BASEL (CH) | 2013-01-10 | — | — | WO | claimed |
| EP-1011656-A2 | A METHOD FOR TREATING TENSION-TYPE HEADACHE | Head Explorer ApS (DK) | 2000-06-28 | — | — | EP | claimed |
| WO-1998019674-A2 | A METHOD FOR TREATING TENSION-TYPE HEADACHE | HEAD EXPLORER APS (DK) | 1998-05-14 | — | — | WO | claimed |
| CN-108367043-A | The conjugate of quaternized tubulysin compound | 西雅图基因公司 | 2018-08-03 | — | — | CN | disclosed |
| WO-2013004716-A1 | PEPTIDE BEADS | UNIVERSITÄT BASEL (CH) | 2013-01-10 | — | — | WO | disclosed |
| EP-1829539-A2 | A method for treating tension-type headache | HEADEXPLORER ApS (DK) | 2007-09-05 | — | — | EP | disclosed |
| US-20050074448-A1 | Increasing nitric oxide production; nitric oxide synthase havingTAT protein transduction domain; vascular diseases | THE CURATOR SOF THE UNIVERSITY OF MISSOURI | 2005-04-07 | — | — | US | disclosed |
| US-20040097562-A1 | Method for treating tension-type headache | HEAD EXPLORER APS (DK) | 2004-05-20 | — | — | US | disclosed |
| US-6649605-B2 | Administering amount of agent effective to interact with neuronal transmission connected with pain perception, so as to prevent or reduce central sensitization | HEAD EXPLORER A/S (DK) | 2003-11-18 | — | — | US | disclosed |
| US-20020072543-A1 | Method for treating tension-type headache | NEURAXON INC. (CA) | 2002-06-13 | — | — | US | disclosed |
| EP-1132082-A1 | Use of substances capable of blocking the production of glutamate for treating tension-type headache | Head Explorer ApS (DK) | 2001-09-12 | — | — | EP | disclosed |
| US-6284794-B1 | Method for treating tension-type headache with inhibitors of nitric oxide and nitric oxide synthase | HEAD EXPLORER APS (DK) | 2001-09-04 | — | — | US | disclosed |
| EP-1011656-A2 | A METHOD FOR TREATING TENSION-TYPE HEADACHE | Head Explorer ApS (DK) | 2000-06-28 | — | — | EP | disclosed |
| WO-1998019674-A2 | A METHOD FOR TREATING TENSION-TYPE HEADACHE | HEAD EXPLORER APS (DK) | 1998-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072543-A1 | Method for treating tension-type headache | HNMT, NNMT, GRIN2A | C3AR1 3112/4885SIRT5 313/4885CACNA1B 114/4885 |
| US-20040097562-A1 | Method for treating tension-type headache | GRIN3A, GRIN2A, GRIK4 | C3AR1 4591/4885SIRT5 286/4885CACNA1B 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.